ESLA Q2 2025 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$6M

EPS (Diluted)

$-0.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$414,879

Free Cash Flow

-$414,879

Stock-Based Comp.

$159,098

Balance Sheet

Total Assets

$3M

Total Liabilities

$9M

Stockholders' Equity

-$6M

Cash & Equivalents

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$4M	-40.4%
Net Income	-$6M	-$4M	-40.3%